Tiziana Life Sciences (TLSA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tiziana Life Sciences is expanding its Phase 2 trial for intranasal foralumab, a novel treatment for non-active secondary progressive multiple sclerosis (SPMS), to include prestigious U.S. medical centers like Yale and Johns Hopkins. This move aims to address the significant unmet need for SPMS therapies by leveraging top-tier research facilities and minimizing PET scan variability. Tiziana’s innovative approach targets inflammation without systemic immune suppression, underscoring its potential in treating complex neurodegenerative diseases.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.